More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/YM-254890 [568580-02-9]
Chemical Structure
Chemical Structure
Chemical Structure

YM-254890 [568580-02-9]

Research Use Only
AG-CN2-0509
AdipoGen Life Sciences
CAS Number568580-02-9
DownloadMSDS
Product group Chemicals
Estimated Purity>95%
Molecular Weight960.1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    YM-254890
  • Delivery Days Customer
    10
  • CAS Number
    568580-02-9
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Molecular Formula
    C46H69N7O15
  • Molecular Weight
    960.1
  • Scientific Description
    Chemical. CAS: 568580-02-9. Formula: C46H69N7O15. MW: 960.1. Cyclic depsipeptide composed of unique amino acids differing from normal amino acids. Membrane permeable, potent and selective Galphaq family inhibitor. Inhibits the signal transduction of Galphaq, Galpha11 and Galpha14 (IC50=0.095microM) by blocking the exchange of GDP for GTP, preventing the activation of the G protein. Inhibits platelet aggregation induced by ADP. Shown to inhibit Galphaq-coupled GPCR signaling by inhibiting calcium mobilization and to have antithrombotic and thrombolytic effects. Might be used as a starting point for new approaches in cancer drug discovery. Galphaq signaling has been shown to regulate brown/beige adipocytes using the structurally similar specific Galphaq family inhibitor FR900359. It is suggested that inhibition of this pathway may be a novel therapeutic approach to combat obesity. The closely related compounds YM-254890 and FR900359 (UBO-QIC) are both potent and selective Galphaq family inhibitors and were for long time only restricted accessible. The commercial availablilty of YM-254890 might give further insights into Galphaq family singaling processes. - Cyclic depsipeptide composed of unique amino acids differing from normal amino acids. Membrane permeable, potent and selective Galphaq family inhibitor. Acts in both in vivo and in vitro systems. Inhibits the signal transduction of Galphaq, Galpha11 and Galpha14 (IC50=0.095microM) by blocking the exchange of GDP for GTP, preventing the activation of the G protein. Inhibits platelet aggregation induced by ADP. Shown to inhibit Galphaq-coupled GPCR signaling by inhibiting calcium mobilization and to have antithrombotic and thrombolytic effects. Might be used as a starting point for new approaches in cancer drug discovery. Galphaq signaling has been shown to regulate brown/beige adipocytes using the structurally similar specific Galphaq family inhibitor FR900359. It is suggested that inhibition of this pathway may be a novel therapeutic approach to combat obesity. The closely related compounds YM-254890 and FR900359 (UBO-QIC) are both potent and selective Galphaq family inhibitors and were for long time only restricted accessible. The commercial availability of YM-254890 might give further insights into Galphaq family signaling processes.
  • SMILES
    O=C(N(C)C(C(N[C@H](C(N(C)[C@H](C(N[C@@H]([C@@H](C(C)C)OC([C@@H](NC(C)=O)[C@@H](C(C)C)O)=O)C1=O)=O)C)=O)C)=O)=C)[C@H](OC([C@@H](NC(C)=O)[C@@H](C)OC([C@@H](N1C)[C@@H](C)OC)=O)=O)CC2=CC=CC=C2
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666: M. Taniguchi, et al.; J. Antibiot. 56, 358 (2003)
  • A novel Galphaq/11-selective inhibitor: J. Takasaki, et al.; J. Biol. Chem. 279, 47438 (2004)
  • Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice: T. Kawasaki, et al.; Thromb. Haemost. 94, 184 (2005)
  • Effect of YM-254890, a specific G(alpha)q/11 inhibitor, on experimental peripheral arterial disease in rats: T. Uemura, et al.; Eur. J. Pharmacol. 536, 154 (2006)
  • Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule: A. Nishimura, et al.; PNAS 107, 13666 (2010)
  • Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors: X.F. Xiong, et al.; Nat. Chem. 8, 1035 (2016)
  • Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, Galpha/q,11: D. Kamato, et al.; Front. Cardiovasc. Med. 2, 14 (2015) (Review)
  • Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhibitor: H. Kaur, et al.; Org. Lett. 17, 492 (2015)
  • Gaq proteins: molecular pharmacology and therapeutic potential: D. Kamato, et al.; Cell. Mol. Life Sci. (Epub ahead of print) (2016) (Review)
  • The Gq signalling pathway inhibits brown and beige adipose tissue: K. Klepac, et al.; Nat. Commun. 7, 10895 (2016)